Scarica l'app Stockscreener
34.10
4.11%
-1.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Harrow Inc Borsa (HROW) Ultime notizie
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - Sahm
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st
Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada
Harrow Health Projects Robust Growth After Strong 2025 - TipRanks
HARROW INCHROW 8 5/8 04/30/26 (HROWL) Earnings History & Surprises - ChartMill
Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir
Harrow, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st
HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat
HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - mx.advfn.com
Buy or Sell Harrow Stock? - Trefis
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance
A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st
HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat
Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail
H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK
Harrow stock stabilizes after major Tuesday drop - Nashville Post
Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus
Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis
Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis
With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis
Harrow 2026 slides: ophthalmic firm targets $357M revenue amid stock decline - Investing.com
Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus
Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan
William Blair reiterates Harrow Health stock rating on ophthalmic growth - Investing.com
Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossHROW - Nasdaq
Why Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) - Benzinga
Harrow Q4 Earnings Call Highlights - MarketBeat
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
Harrow Health, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand - GlobeNewswire
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday.com
Harrow Q4 2025 Earnings Report: Revenue $89.1M, Net Income $6.6MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):